AI
ITOS

Atom Investors’s iTeos Therapeutics ITOS Stock Holding History

Atom Investors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,200
Closed -$231K – 328
2022
Q2 		$231K Buy
11,200
+2,234
+25% +$53K 0.1% 170
2022
Q1 		$289K Buy
+8,966
New +$326K 0.14% 144
2021
Q2 		– Sell
-11,261
Closed -$385K – 289
2021
Q1 		$385K Buy
+11,261
New +$407K 0.06% 171

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Atom Investors's ITOS Position: Q3 2022 in Review

Atom Investors sold out of iTeos Therapeutics (ITOS) in Q3 2022, closing a stake of 11,200 shares — an estimated $231K sold.

Atom Investors first reported a position in ITOS in Q1 2021 and held it in 3 quarters. The position peaked at $385K in Q1 2021. 143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

  • Atom Investors reported no remaining iTeos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Atom Investors sold 11,200 iTeos Therapeutics shares in Q3 2022, an estimated $231K.
  • Atom Investors first reported a position in iTeos Therapeutics in Q1 2021 and held it in 3 quarters.
  • Atom Investors's iTeos Therapeutics position peaked at $385K in Q1 2021.
  • 143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on Atom Investors's 13F filing for Q3 2022, filed 8 Nov 2022.